DAB1 and Alzheimer disease: Single-target IHC in a non-AD control with Aβ plaques (Thal phase 3) but no overt pTau pathology (NFT stage 0) revealed multiple, globular plaque-associated Dab1 accumulations that were most prominent in L5 and L3 (Ext Fig 9.2), with little or no pTau or pPSD95Thr19 evident in serial sections.